Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Magazine"

Neuroleptic Malignant Syndrome: diagnosis and treatment

Malin D.
Moscow Research Institute of Psychiatry, Branch ofFederal Medical Research Center of Psychiatry and Narcology of Health Ministry of Russia

Summary

This publication presents recommendations for the diagnosis, differential diagnosis and treatment of neuroleptic malignant syndrome, developing in patients with schizophrenia and schizoaffective disorder. The work gives detailed descriptions of clinical manifestations of NMS, presented diagnostic criteria and differential diagnosis, differentiated approaches to therapy. The publication is based on the analysis of own long-term research studies on the treatment of patients with urgent conditions in psychiatry, as well as the modern results of national and international research on this issue.

Contact: doctormalin@gmail.com

References: 
  • 1. Malin D.I. Pobochnoe deistvie psikhotropnykh sredstv. – M.: Vuzovskaya kniga, 2000. – 207 s.
  • 2. Tsygankov B.D. Kliniko-patogeneticheskie zakonomernosti razvitiya febril'nykh pristupov shizofrenii i sistema ikh terapii. – M.: Norma, 1997. – 232 c.
  • 3. Caroff S.N. The neuroleptic malignant syndrome // J Clin Psychiat. –1980. – Vol. 41, No 3. – P. 1–26.
  • 4. Levenson J.L. Neuroleptic malignant syndrome // Amer J Psychiat. – 1985. – Vol. 142, No 10. – P. 1137–1145.
  • 5. Moscovich M., Novak F., Fernandes A. et al. Neuroleptic malignant syndrome // Arq Neuropsiquiatr. – 2011. – Vol. 69 (5). – P. 751–755.
  • 6. Reulbach U.,Dutsch C., Biermann T. et al. Managing an effective treatment for neuroleptic malignant syndrome // Critical Care. – 2007. – Vol. 11. – P. 4–10.
  • 7. Strawn J.R., Keck P.E., Caroff S.N. Neuroleptic malignant syndrome // Am J Psychiatry. – 2007. – Vol. 164. – P. 870–876.
  • 8. Spivak B., Malin D., Kozirev V. et al. Frequensy of neuroleptic malignant syndrome in a large psychiatric hospital in Moscow // Eur Psychiatry – 2000. – Vol. 15. – P. 330–333.
  • 9. Caroff S.N., Mann S.C. Neuroleptic malignant syndrome // Psychopharmacol Bull. – 1988. – Vol. 24. – P. 25–29.
  • 10. Keck P.E., Pope H.G., McElroy S.L. Declining Frequency of Neuroleptic Malignant Syndrome in a Hospital Population // Amer J Psychiat. – 1991. – Vol. 148, No 7. – P. 880–882.
  • 11. Keck P.E, Pope H.G., Cohen B.M., McElroy S.L., Nierenberg A.A. Risk factors for neuroleptic malignant syndrome. A case-control study // Arch Gen Psychiatry. – 1989. – Vol. 46. – P. 914–918.
  • 12. Norgard N.B., Stark J.E. Olanzapine-associated neuroleptic malignant syndrome // Pharmacotherapy. – 2006. – Vol. 26. – P. 1180–1182.
  • 13. Spivak B. Malin D., Vered Y. et al. Prospective evaluation of circulatory levels of catecholamines and serotonin in neuroleptic malignaut syndrome // Acta Psychitr Scand. – 2000. – Vol. 101. – P. 226–230.
  • 14. Avrutskii G.Ya., Raiskii V.A., Tsygankov B.D. Klinika i techenie zlokachestvennogo neirolepticheskogo sindroma (ostroi febril'noi neirolepticheskoi entsefalopatii) // Zhurn. nevropatol. i psikhiatr. – 1987. – Vyp. 9. – S. 1391–1396.
  • 15. Chekhonin V.P., Morozov G.V., Morkovkin V.M., Kekelidze Z.I. Immunokhimicheskoe izuchenie pronitsaemosti gematoentsefalicheskogo bar'era pri kriticheskikh sostoyaniyakh, obuslovlennykh febril'noi shizofreniei i ostrymi alkogol'nymi entsefalopatiyami // Mat. 8 s"ezda nevropat. i psikhiatr. – M., 1988. – T. 3. – S. 132–134.
  • 16. Kekelidze Z.I., Chekhonin V.P. Kriticheskie sostoyaniya v psikhiatrii. – M.: GNTsSSP im. V.P. Serbskogo, 1997. – 362 s.
  • 17. Mosolov S.N., Kostyukova E.G., Serditov O.V. Cerotoninovyi sindrom pri lechenii depressii // Mezhdunarodnyi zhurnal meditsinskoi praktiki. – 2000. – № 8. – S. 28–33.
  • 18. Mosolov S.N. Kostyukova E.G., Serditov O.V. Serotoninovyi sindrom pri lechenii depressii // Novye dostizheniya v terapii psikhicheskikh zabolevanii / pod red. S.N. Mosolova. – M.: BINOM, 2002. – S. 317–330.
  • 19. Romasenko V.A. Gipertoksicheskaya shizofreniya. – M.: Meditsina, 1967. – 240 s.
  • 20. Tiganov A.S. Febril'naya shizofreniya: klinika, patogenez, lechenie. – M.; Meditsina, 1982. – 128 s.
  • 21. Stauder K.N. Die todliche Katatonie // Arch Psychiat Nervenkr. – 1934. – Bd. 102. –S. 614–634.
  • 22. Volkov V.P. K voprosu o febril'noi katatonii // Sotsial'naya i klinicheskaya psikhiatriya. – 2012. – № 2. – S. 16–20.
  • 23. Ghaziuddin N., Alkhouri I., Champine D. et al. ECT treatment of malignant catatonia/NMS in an adolescent: a useful lesson in delayed diagnosis and treatment // J ECT. – 2002. – Vol. 18, No 2. – P. 95–98.
  • 24. Moshchevitin S.Yu., Tsygankov B.D., Malin D.I. Effektivnost' elektrosudorozhnoi terapii v svete sovremennykh podkhodov k lecheniyu febril'nykh sostoyanii shizofrenii // Zhurn. nevropatol. i psikhiatr. – 1990. – № 4. – S. 114–12.
  • 25. Patel A.L., Shaikh W.A., Khobragade A.K. et al. Electroconvulsive Therapy in Drug Resistant Neuroleptic Malignant Syndrome // JAPI. – 2008. – Vol. 56. – P. 49–50.
  • 26. Trollor J.N., Sachdev P.S. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases // Aust NZ J Psychiatry. – 1999. – Vol. 33. – P. 650–659.
  • 27. Malin D.I. Effektivnost' primeneniya plazmafereza v lechenii pobochnykh effektov i oslozhnenii neirolepticheskoi terapii // Zhurn. sotsial'noi i klinicheskoi psikhiaptrii. – 1993. – № 4. – S. 82–84.
  • 28. Malin D.I., Ravilov R.S., Kozyrev V.N. Effektivnost' bromokriptina i dantrolena v kompleksnoi terapii zlokachestvennogo neirolepticheskogo sindroma // Rossiiskii psikhiatricheskii zhurnal. – 2008. – № 5 – S. 75–81.
  • 29. Sakkas P.L., Davis J.M., Janicak P.G., Wang Z.Y. Drug treatment of the neuroleptic malignant syndrome // Psychopharmacol Bull. – 1991. – Vol. 27. – P. 381–384.
  • 30. Mosolov S.N., Tsukarzi E.E., Malin D.I. Neotlozhnaya pomoshch' v psikhiatrii // Meditsina kriticheskikh sostoyanii. – 2004. – № 6. – S. 36–41.
  • 31. Pope H.G., Aizley H.G., Keck P.E., McElroy S.L. Neuroleptic malignant syndrome: long-term follow-up of 20 cases // J Clin Psychiatry. – 1991. – Vol. 52. – P. 208–212.
  • 32. Manu P., Sarpal D., Muir O., et al. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature // Schizophr Res. – 2011. – Vol. 134. P. 180–186